Respiratory Syncytial Virus (RSV), a major cause of bronchiolitis and pneumonia

HIPRA, together with CURAPATH, Biotechvana S.L. and Nostrum Biodiscovery, will investigate a new vaccine against respiratory syncytial virus (RSV). It will be possible through the program "Misiones Ciencia e Innovación” (“Science and Innovation Missions”, in English).

“Misiones Ciencia e Innovación” is a program with the aim of promoting research, improving company technology and stimulating public-private cooperation in R&D.

HIPRA's "mission" is based on a project to investigate a new vaccine against RSV, which causes bronchiolitis and pneumonia, which affects all ages and, especially, very young children from all over the world.

“Misiones Ciencia e Innovación” program is part of the “Plan de Recuperación, Transformación y Resiliencia” (“Recovery, Transformation and Resilience Plan”, in English) and is articulated through the Centro para el Desarrollo Tecnológico Industrial (CDTI) (Center for Industrial Technological Development”, in English), an entity dependent on the Ministry of Science and Innovation.